Data in Brief (Dec 2021)
Method of contraception and risk of ovarian cancer data
Abstract
The data presented here were obtained for a New Zealand nationwide population-based case-control analysis undertaken to assess the association between ovarian cancer and depot medroxyprogesterone acetate (DMPA), intrauterine contraceptive devices (IUDs), and vasectomy of a woman's sexual partner (Chesang et al., 2021). The research involved women aged 35 to 69 years. Controls were randomly selected from the New Zealand electoral roll. Cases were women with a diagnosis of incident ovarian cancer recruited from the New Zealand Cancer Registry and had to be listed on the electoral roll.Data collection was conducted between 1st May 2013 and 31st October, 2015. A structured postal questionnaire was used to gather information. Data were analysed using IBM Statistical Package for the Social Sciences (IBM SPSS statistics 22). Odds ratios adjusted for age were calculated using the method of Mantel and Haensze (Rosner et al., 2007). For multivariable analyses, binary logistic regression was used.Description of study participants and age-adjusted and multivariable analyses of the association between ever-use and specifics of use of DMPA, IUDs, and vasectomy were presented in a journal article (Chesang et al., 2021). Here, we present data from analyses of the risk of ovarian cancer by histological type associated with the use of DMPA, IUDs and ever having had a vasectomised partner. In addition, analyses assessing the association between ovarian cancer and these contraceptives restricted to ever-users and never-users of hormonal contraceptives (defined as oral contraceptives or DMPA) are presented. Data from analyses of the association between history of tubal ligation and the risk of ovarian cancer are also presented.These data, including the findings of a related study (Chesang et al., 2021) and the raw data, can be included in a collaborative analysis of existing studies undertaken to assess the association between IUDs, long-acting progestogen-based contraceptives, and partner vasectomy and the risk of ovarian cancer.
